Metagenomi Therapeutics (MGX) vs Quince Therapeutics (QNCX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Metagenomi Therapeutics (MGX) has outperformed Quince Therapeutics (QNCX) over the past year, losing 68.9% versus a loss of 92.4%. Metagenomi Therapeutics is the larger company by market cap ($37.5 million vs $29.9 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MGX | QNCX |
|---|---|---|
| Share price | $0.9932 | $29.36 |
| Market cap | $37.52M | $29.86M |
| 1-day change | +0.86% | +9.88% |
| YTD return | -38.69% | -95.62% |
| 1-year return | -68.87% | -92.35% |
| 5-year return | — | -99.77% |
| EPS (TTM) | $-2.49 | $-214.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.95 | $910.00 |
| 52-week low | $0.96 | $15.10 |
| Distance from 52-week high | -74.86% | -96.77% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +604.79% | +156.91% |
| Average volume | 155.71K | 28.49K |
| Shares outstanding | 37.78M | 1.02M |
| Employees | 113 | 38 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGX has outperformed QNCX by 23.5 percentage points over the past year.
About Metagenomi Therapeutics
MGX stock →Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States.
Healthcare · Biotechnology · 113 employees
About Quince Therapeutics
QNCX stock →Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
Healthcare · Biotechnology · 38 employees
MGX vs QNCX FAQ
Which is bigger, Metagenomi Therapeutics or Quince Therapeutics?
Metagenomi Therapeutics (MGX) is larger, with a market capitalization of $37.52M compared with $29.86M for Quince Therapeutics (QNCX).
Which stock has performed better over the past year, MGX or QNCX?
MGX returned -68.87% over the past 12 months, compared with -92.35% for QNCX (price return, excluding dividends). Past performance does not predict future results.
Are Metagenomi Therapeutics and Quince Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.